Clinical Trial Update: Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating neoadjuvant sintilimab with chemotherapy for resectable non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN